Literature DB >> 10673238

Leukotrienes in cardiovascular diseases.

G Folco1, G Rossoni, C Buccellati, F Berti, J Maclouf, A Sala.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10673238     DOI： 10.1164/ajrccm.161.supplement_1.ltta-22

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  10 in total

1.  Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT(2)) receptor.

Authors:  F Wunder; H Tinel; R Kast; A Geerts; E M Becker; P Kolkhof; J Hütter; J Ergüden; M Härter
Journal:  Br J Pharmacol       Date:  2010-05       Impact factor: 8.739

2.  CysLT1 leukotriene receptor antagonists inhibit the effects of nucleotides acting at P2Y receptors.

Authors:  Liaman Mamedova; Valérie Capra; Maria Rosa Accomazzo; Zhan-Guo Gao; Silvia Ferrario; Marta Fumagalli; Maria P Abbracchio; G Enrico Rovati; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2005-11-08       Impact factor: 5.858

Review 3.  The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field.

Authors:  Malvina Hoxha; G Enrico Rovati; Aurora Bueno Cavanillas
Journal:  Eur J Clin Pharmacol       Date:  2017-04-04       Impact factor: 2.953

4.  Endothelial cysteinyl leukotriene 2 receptor expression mediates myocardial ischemia-reperfusion injury.

Authors:  Wei Jiang; Sean R Hall; Michael P W Moos; Richard Yang Cao; Satoshi Ishii; Kofo O Ogunyankin; Luis G Melo; Colin D Funk
Journal:  Am J Pathol       Date:  2008-02-14       Impact factor: 4.307

5.  Inhibition of leukotriene synthesis with MK-886 prevents a rise in blood pressure and reduces noradrenaline-evoked contraction in L-NAME-treated rats.

Authors:  Françoise Stanke-Labesque; Gaëlle Hardy; Françoise Caron; Jean-Luc Cracowski; Germain Bessard
Journal:  Br J Pharmacol       Date:  2003-07-29       Impact factor: 8.739

6.  Hyaluronidase decreases neutrophils infiltration to the inflammatory site.

Authors:  Marcio Fronza; Cornélia Muhr; Denise Sayuri Calheiros da Silveira; Carlos Artério Sorgi; Stephen Fernandes de Paula Rodrigues; Sandra Helena Poliselli Farsky; Francisco Wanderley Garcia Paula-Silva; Irmgard Merfort; Lúcia Helena Faccioli
Journal:  Inflamm Res       Date:  2016-03-04       Impact factor: 4.575

7.  Cysteinyl leukotrienes regulate endothelial cell inflammatory and proliferative signals through CysLT₂ and CysLT₁ receptors.

Authors:  Ernest Duah; Ravi K Adapala; Nosayba Al-Azzam; Vinay Kondeti; Farai Gombedza; Charles K Thodeti; Sailaja Paruchuri
Journal:  Sci Rep       Date:  2013-11-20       Impact factor: 4.379

Review 8.  Role of the Cysteinyl Leukotrienes in the Pathogenesis and Progression of Cardiovascular Diseases.

Authors:  Francesca Colazzo; Paolo Gelosa; Elena Tremoli; Luigi Sironi; Laura Castiglioni
Journal:  Mediators Inflamm       Date:  2017-08-28       Impact factor: 4.711

9.  Combined Machine Learning and GRID-Independent Molecular Descriptor (GRIND) Models to Probe the Activity Profiles of 5-Lipoxygenase Activating Protein Inhibitors.

Authors:  Hafiza Aliza Khan; Ishrat Jabeen
Journal:  Front Pharmacol       Date:  2022-03-01       Impact factor: 5.810

Review 10.  Arachidonic Acid Metabolites in Cardiovascular and Metabolic Diseases.

Authors:  Thomas Sonnweber; Alex Pizzini; Manfred Nairz; Günter Weiss; Ivan Tancevski
Journal:  Int J Mol Sci       Date:  2018-10-23       Impact factor: 5.923
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.